US biotech security commission warns China is moving faster on brain-computer interfaces
The NSCEB calls for clearer FDA pathways, Medicare coverage, shared neural data infrastructure and better federal coordination for BCIs.
The National Security Commission on Emerging Biotechnology (NSCEB), a body created by Congress, has published an analysis of US leadership in brain-computer interfaces. It notes that the US led BCI research but China was first to approve an implanted BCI for commercial use, in March 2026 (our coverage). It identifies four bottlenecks: poor federal coordination, technical limits such as signal degradation, fragmented data, and unclear FDA and CMS pathways.
Its recommendations include a national biotechnology coordination office, shared infrastructure for neural and clinical data, and adding BCIs to faster FDA/CMS review and coverage programs. Such reports often shape later legislation.
Learn more: Clinical trial pathway · Neural data